D-407 Transfection Reagent (Retina Pigment Epithelial)


Kit Size VolumePricePay with CC, PO, or PaypalAdd to Cart
0.5 ml (Catalog #1743)$363.00
1.5 ml CRISPR (Catalog #2135)$719.00
1.5 ml (Catalog #1744)$719.00
8.0 ml (Catalog #7033)$1,857.00
SKU: D407 Category:


Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Transfection Reagent for D-407 Cells (Retinal Pigment Epithelial Cells)

  • Proprietary cationic lipids formulation
  • High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
  • Kit includes Transfection Enhancer reagent
  • Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
  • A proven reagent for establishing stable cell lines
  • Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
  • Download in vitro D-407 transfection protocol: [PDF]
  • Download D407 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for D407 cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089753
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

Enhanced transfection kit designed for superior efficiency in the D407 cell line, a human retinal pigment epithelial cells.

Transfection Protocol and SDS:

Download Altogen Biosystems D407 Transfection Protocol: [PDF]

Download SDS: [PDF]

D407 Cell Line:

Despite recent breakthroughs in the treatment and prevention of eye diseases that lead to blindness, there are still many causes of visual impairment for which there is no treatment. Preclinical studies of the retinal pigment epithelium (RPE) can help to overcome obstacles in finding new treatments for age-related macular degeneration (AMD), the primary cause of blindness in the world. Retinal pigment epithelium (RPE) is a layer of cells in the eye that provides nourishment to retinal cells and performs a variety of functions related to the upkeep of normal vision. Over time the RPE degenerates and leads to a variety of vision disorders. The D-407 cell line was derived from human RPE cells and is a valuable research tool in the study of vision impairment. This cell line is useful in studies of human eye cells, further investigation of this cell line could produce potential medical treatments for the visually impaired.  D-407 cells exhibit phagocytic activity and are used widely in molecular and cell biology research. Research carried out via transfection on the D-407 RPE cell line could lead to the development of treatments that could help restore vision in patients. Altogen Biosystems provides lipid-based transfection reagent kits for the D-407 retinal pigment epithelium cell line that has produced consistent results in the establishment of stable cell lines. The D407 cell line is a human retinal pigment epithelial cell line that was originally derived from a 19-year-old donor. It has been extensively used as a model system for studying various retinal diseases, including age-related macular degeneration and diabetic retinopathy. These cells are commonly used in vitro to study the effects of drugs and toxins on retinal pigment epithelial cells, as well as to investigate molecular mechanisms involved in the development and progression of retinal diseases. They are also used for studying the pathogenesis of ocular infections.


Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the D-407 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated.


Figure 2. Protein expression of GAPDH in D-407 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into D-407 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems manufacturers over 100 pre-optimized in vitro transfection kits for cancer cell lines and primary cells, elecroporation products, and  tissue-targeted in vivo delivery reagents for life science research. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides safety and efficacy preclinical research services. GLP-compliant studies for IND applications, and drug development, including over 90 in-house validated xenograft models, safety toxicology, etc (visit AltogenLabs.com).

D407 Transfection Reagent

Volume Options:

  • 0.5 ml (Catalog #1743)
  • 1.5 ml (Catalog #1744)
  • 1.5 ml CRISPR (Catalog #2135)
  • 8.0 ml (Catalog #7033)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Additional information

Weight 1 lbs
Dimensions 4 × 3 × 0.2 in
Kit Size (Volume)

0.5 ml (Catalog #1743), 1.5 ml (Catalog #1744), 1.5 ml CRISPR (Catalog #2135), 8.0 ml (Catalog #7033)